Kimberly-Clark Acquires Kenvue for $48.7 Billion

Kimberly-Clark is acquiring Kenvue in a cash and stock deal valued at approximately $48.7 billion, creating one of the largest consumer health goods companies. Kimberly-Clark shareholders are expected to own about 54% of the combined entity, with Kenvue shareholders holding 46%. The deal, expected to close in the second half of next year, aims for $1.9 billion in cost savings within three years and will generate about $32 billion in annual revenue. Kenvue, which was spun off by Johnson & Johnson two years ago, has faced scrutiny over its Tylenol product due to unproven claims by Donald Trump and Robert F. Kennedy Jr. linking it to autism. Kimberly-Clark Chairman and CEO Mike Hsu will lead the merged company, which will retain Kimberly-Clark's headquarters in Irving, Texas, while maintaining a significant presence at Kenvue's locations.